| 摘要 |
<p>The invention provides ATP(CTP) : tRNA nucleotidyltransferase (CCA1) as a novel antifungal target, screening methods for CCA1 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine. Specifically in the treatment of an individual susceptible to or suffering from an anti-fungal infection. In particular the compounds find use in the treatment of topical or mucosal (e.g. thrush and vaginal candidiasis) fungal infections, e.g. caused by fungus of the Candida species, and for systemic infections, e.g. caused by fungi of Candida and Aspergillus species, such as but not limited to C. Albicans, Aspergillus flavus or Aspergillus fumigatus.</p> |
